



Showcasing UK's most
successful biotech super-cluster



BioTrinity 2008 Oxford

15 - 16 April 2008

The Quadrangle at Kassam Stadium

www.biotrinity.com

PRELIMINARY PROGRAMME

Organised by



BioTrinity 2008 Sponsors and Partners

Platinum Sponsors:



Gold Sponsors:



Silver Sponsors:



Bronze Sponsors:



Marketing & Communications Agent:



Project Partners:



Partnering by:



BioTrinity 2008 - Oxford

OBN's flagship annual biopartnering conference showcases the most promising emerging and clinical stage companies in the Oxford & South East BioCluster. Companies in this cluster alone have completed financings worth over £324m since 2005*, with the total value of M&A deals being £530m, a total of over €1.14bn

Dear Colleague

I am really excited about presenting BioTrinity 2008 Oxford to the biotech community after the remarkable success of OBN's inaugural biopartnering conference last year, which attracted over 400 delegates, hosted over 500 meetings and featured over 180 licensing opportunities.

By now, I hope most of you have heard about our excellent conference. I am pleased to note the early involvement of pharmas including AstraZeneca, Merck, Shire and Genzyme as well as VCs such as Sofinnova, Atlas, Innovator Capital and Oxford Capital Partners; and a list of emerging biotechs too long to include here.

On behalf of OBN, I am very grateful for the support of our community, especially our many sponsors, project partners, speakers and exhibitors.

Details of the programme are in this booklet, but over the coming weeks as the programme is finalised, I think you'll be pleased by the diversity of the participants in the four panel discussions, as we tackle the key issues for the industry and the rapidly growing list of companies confirmed as attending which surpassed 100 even earlier than last year.

In terms of doing deals, we're making a unique offer at BioTrinity 2008 Oxford: large, light and airy private partnering rooms which can hold up to 10 delegates at a time allow you to bring your decision-making team to do business with the best at BioTrinity.

So do browse at the following pages to peek further into the programme and get a glimpse of some of the companies with whom you will have an opportunity to partner.

I look forward to seeing you in April.

Jon Rees, PhD - Network Director, OBN

Who will you meet at BioTrinity?

- ✧ Promising emerging and clinical stage SMEs
- ✧ Medium-sized and large biotechnology and healthcare companies
- ✧ Leading academics, researchers and their technology transfer commercial managers
- ✧ Investors and entrepreneurs

Why our delegates came last year*

- ✧ Meet new contacts and renew contacts for business development
- ✧ Keep up-to-date of new developments
- ✧ Raise and maintain your company profile
- ✧ Seek out potential partners and deals
- ✧ Identify new collaborators, partners and suppliers

*Gathered from what they told us in feedback

Why attend?

91% of delegates rated the conference as excellent or good
 88% of delegates rated one-to-one partnering as excellent or good


"many thanks for organising a great meeting - it was highly informative, a great place to network, bounce "problems and ideas" off of other executives and get expert advice. Looking forward to next year's meeting."

Mohammad S Alavijeh, Co-founder and Managing Director, Pharmidex Pharmaceutical Services Ltd
 29th March 2007, following the inaugural BioTrinity conference.

Take a look at BioTrinity 2007 statistics


BioTrinity 2007 attendees by Position

- 25% Top Management
- 23% Senior Management
- 52% Middle Management




BioTrinity 2007 attendees by Industry/sector

- 45% Biotech and Healthcare
- 27% Service Provider
- 8% Academia
- 3% Bioinformatics
- 3% Investor
- 9% Non for Profit
- 1% Government
- 4% Unclassified



BioTrinity 2007 International Attendees by Country

- 2% Australia
- 12% Belgium
- 5% Canada
- 5% Denmark
- 7% France
- 7% Germany
- 10% Ireland
- 20% Netherlands
- 7% Switzerland
- 25% USA



BioTrinity 2008 programme features

Multi track presentations:

- ↳ Showcasing the most promising Emerging Companies and Clinical Stage Developments
- ↳ Panel discussions on VC, liquidity and partnering
- ↳ Key notes on the Growth and Development of the sector
- ↳ Technology showcase of licensing opportunities and spin outs
- ↳ Sponsor-led, independent workshops on deal making, funding, business planning and alliance
- ↳ Key deals from Leading Growth companies
- ↳ Bio-IT Showcase of biotech informatics solutions

Partnering

An online interactive one-to-one partnering system to enable companies to select suitable partners. This year we have the capacity to hold up to 800 half-hour meetings over the 2 conference days in private rooms and a further 100+ meetings in open tables should we exceed our expectations.

Networking with the best of the super-cluster

- ↳ Networking wine and canapes reception on Tuesday 15 April, featuring the celebration of the OBN 2008 BioCluster Report launch. Companies who have booked exhibition space will have the chance to display their exhibits during this event.
- ↳ Conference Close drinks on Wednesday 16 April, marking the close of what we hope will be a successful and fulfilling event.
- ↳ Both events will take place amidst the exhibitors, catering and partnering terminals, providing excellent opportunities to network.
- ↳ Ample opportunities to network further during the breakfast, tea/coffee breaks, lunches and quite zone area.

A high visibility exhibition amidst partnering terminals, catering and networking areas.

BioTrinity Preliminary Programme

Tuesday 15 April 2008

- 09:00 Welcome
- 09:05 VIP address
- 09:15 Plenary talk
- 09:30 Key Deals

10:00 **TEA/COFFEE BREAK**

TRACK 1

- 10:30 Panel Discussion: Liquidity alternatives to the big step: Leveraging opportunities to achieve your economic goals.
- 11:00 Panel Discussion: How to Realise Value in Biotech Partnering & Financing
 - ✦ Charles Macfarlane (chair), Non-Executive Director, **PharmaVentures Ltd** and previously Executive Director Worldwide Alliances, Licensing & Acquisitions at Proctor & Gamble
 - ✦ Shaun Grady, Vice President Deal Management, Strategic Planning and Business Development, **AstraZeneca**, UK
 - ✦ Charlie Alexander, Director of Business Development, **Shire Pharmaceuticals**
 - ✦ Dr. Kevin J. Scanlon, Founder & **CEO**, **International Bioscience**, USA
 - ✦ Edwin Moses, Chairman and CEO, **Ablynx**

Companies Showcase - Drug Discovery and Development (Therapeutics)

- 11:45 **(OSI) Prosidion** - Anker Lundemose, President Diabetes and Obesity, Clinical Stage Developments
"A UK Contribution to the success of a NASDAQ-listed US Biotech"
- 12:00 **LUNCH and EXHIBITION VIEWING**
- 13:00 **Chroma Therapeutics** - (Oncology)
- 13:15 **Phynova** - Robert Miller, **CEO** (Oncology)
- 13:30 **BioVex** - Dr Colin Love, SVP Product Development (Oncology)
- 13:45 **Celleron Therapeutics** - Nick La Thangue, **CEO** (Oncology)
- 14:00 **Hybrid Systems** - Paul Colford, **CEO** (Oncology)
- 14:15 **Primed** - (Oncology)
- 14:30 **Oxford Genome Sciences** - Christian Rohlff, **CEO** (Oncology)
- 14:45 **Glide Pharma** - Charles Potter, **CEO** (Drug Delivery)
- 15:00 **Biocompatibles** - Donald Coppen, Business Research and Development Manager (Drug Delivery)
- 15:15 **TEA/COFFEE BREAK**
- 16:00 Growth and Development of the Sector

Kurt Laskow-Pooley MBA, Cluster Analyst and Business Development Manager, **OBN**
"OBN BioCluster Report - A Review of Key Findings and Launch"

Key notes review of the findings of the most extensive exercise benchmarking the growth and development of the Oxford BioCluster, and launch of an extensive report detailing every deal, drug and company playing a role in the resurgence.

16.30: OBN BIOCLUSTER REPORT 2008 LAUNCH AND RECEPTION

TRACK 2 Technology Showcase

Spin outs and licensing opportunities from Universities, Institutes and other organisations such as **NHS Innovations**, **MRC Technology**, **Cancer Research Technology**, **Isis Innovation** as well as licensing opportunities from SMEs. Companies and other parties interested in presenting should contact OBN at the earliest opportunity to request a 15 minute presentation slot.

13:00 - 16:00 (10 slots available)

13:00 Spin out (Therapeutics): Magic Tag Immobilisation Technology for chemical genomics approaches to therapeutic switching
Suzanne Dilly - Chief Operating Officer, **a2sp Ltd**

TRACK 3 WORKSHOPS:

Workshop A15: Host: **Fisher Scientific UK**
Workshop B15: IP Diligence
Host: **Manches**
Workshop C15: Navigating the Funding Landscape
Host: Cheryl Scott, **BFAS**
Workshop D15: Do's and Don'ts of Licensing to Big Pharma
Host: Tim Sparey, PhD - **Merck Sharp & Dohme**
Workshop E15: Host: **Genzyme Plc**
Workshop F16: Exploring sources of business intelligence for biotech deal-making
Host: **Thomson Scientific**
Workshop G15: When It Hits The Fan, Can I Be Held Personally Responsible?
Host: Andrew Tamworth, **Giles**

Wednesday 16 April 2008

TRACK 1

09:05-10:00 VC Panel Discussion: Creating Opportunities to Exit a Biotech Business Earlier

Key Notes and Panel Discussion from US, EU and Corporate Venturers who have invested in companies and alliances involving the UK's biotechnology and healthcare industry

- ✧ David Mott (chair) - Investment Director, **Oxford Capital Partners**
- ✧ Zina Affas - Principal (Life Sciences), **Atlas Venture**
- ✧ Graziano Seghezzi - Partner (Life Sciences), **Sofinnova Partners**
- ✧ Two further VCs t.b.a.

10:00 **TEA/COFFEE BREAK**

Company Showcase - Drug Discovery and Development - CNS Therapeutic Focus

- 10.45 **Evotec** - Mark Ashton, EVP Business Development
- 11.00 **Summit Plc** - Steven Lee, **CEO**
- 11.15 **Capsant Neurotechnologies** - Prof Lars Sundstrom, **CSO**

Company Showcase - Drug Discovery and Development - Pain Therapeutic Focus

- 11.30 **Solace Pharma** - Eliot Forster, **CEO**
- 11.45 **Syntaxin** - Patrick Doyle, **CEO**

12:00 **LUNCH and EXHIBITION VIEWING**

Drug Discovery and Development - Inflammatory Disease Therapeutic Focus

- 13:00 Panel Discussion: European GMP Biomanufacturing: Is Bigger More Beautiful
(after LUNCH AND EXHIBITION)
- 13.15 **Chemocentryx** - Thomas Schall, **CEO**
- 13.15 **Epidyme** - Simon McEwen, Director
- 13.45 **Lein Applied Diagnostics** - Graeme Clark, Director
- 14.00 **Oxford BioMaterials** - Nick Skaer, **CEO**
- 14.15 **APA Parafricta** - George Sampson, **CEO** The Preservation of Skin Integrity

16.00 **CONFERENCE CLOSE DRINKS & REFRESHMENTS**

17.00 Closing Notes

TRACK 2

Technology Showcase

Technology Showcase continued (see website for updates)

TRACK 3

Bio-IT Showcase (formerly known as Discovery Informatics Forum)

Companies and other parties interested in presenting should contact OBN at the earliest opportunity to request one of the ten 15 minutes presentation slots.

The Bio-IT showcase is an opportunity for life sciences informatics companies to showcase their offerings.

Time: 13:00 - 16:00

- 13:00 Systems Biology for Cancer Drug Development
Adam Hardey, Business Development and Research, **Physiomics Plc**
- 13:15 Pay per use service (PPU) for bioinformatics software
Dr. Riccardo M. Bennett-Lovsey, Business Development Manager, **Equinox Pharma**
- 13:30 Simon Coles, CTO, **Amphora**
- 14:00 Searching and analyzing biological data and patented sequences,
Dr. Colin Williams, Product Manager Biology & Bioinformatics, **Thomson Scientific**
- 14:30 Title to be announced, Jon Tilbury, Director, **Tessella Support Services plc**

TRACK 4

WORKSHOPS:

- Workshop H16: Host: **SEHTA**
- Workshop J16: Host: **Grant Thornton UK LLP**
- Workshop L16: Host: **UKTI**
- Workshop N16: Host: **RDP Associates**

Partnering

One-to-one Partnering will take place in large, light and airy private partnering rooms* which can take up to 10 people on:

15 April 2008: 0830 hrs - 1730 hrs

16 April 2008: 0830 hrs - 1730 hrs

Registration

Registration is online via <http://www.biotrinity.com/registration.html>

Don't miss the early bird offer - available only to a limited number of delegates!

Registration fees:

- | | |
|--------------------------|---|
| Full OBN members: | Early Birds: £399 + VAT (plus a second ticket free)
Regular registration: £499 + VAT (plus a second ticket free) |
| Associate OBN members: | Early Birds: £399 + VAT
Regular Registration: £499 + VAT |
| Non members: | Early Birds: £499 + VAT
Regular Registration: £599 + VAT |
| One day registration: | Early Birds: £350 + VAT
Regular Registration: £450 + VAT |
| On the day registration: | £800 + VAT |

Registration fee includes:

- ✧ Participation in one-to-one Partnering held in private rooms (meetings can be booked online from 6 weeks prior to the conference)
- ✧ Two networking receptions
- ✧ Access to all conference tracks, panel discussions and workshops for 2 days
- ✧ Free access to Exhibition
- ✧ Conference handbook containing partnering profiles and a full delegate list
- ✧ Lunch and refreshments for two days

Press Registration:

BioTrinity 2008 welcomes credentialed Press free of charge.

Please contact:

Maria Patey at DeFacto Communications

Email: M.patey@defacto.com

Tel: 020 7861 3838

Please note that press passes are necessary to gain entry to the conference.

The Press Room is located on the upper level and is equipped with refreshments, lunch and entry to the networking evenings is also free of charge.

Sponsorship & Promotional Opportunities

We have had excellent support this year in the form of our sponsors, who have taken up the bulk of the packages on offer. Exhibition spaces are sold out, however the following packages and some promotional opportunities are still available. If you require further information on these or wish to discuss further promotional opportunities on offer, please contact Aruna Dudhia on +44 (0)1865 594 641 or aruna.dudhia@oxfordshirebioscience.net or look online.

- ✧ Diamond Sponsorship Package £24,999 + VAT
A unique opportunity for your company to play a major role at BioTrinity 2008 as the only Diamond sponsor
- ✧ Platinum Sponsorship Package - £14,999 +VAT
- ✧ Gold Sponsorship Package - £9,999 + VAT
- ✧ Silver sponsorship package - £4,999 + VAT
- ✧ Bronze sponsorship package - £2,999 + VAT

Meeting Venue

The Quadrangle at Kassam Stadium
Grenoble Road
Oxford OX4 4XP
Tel: +44 (0)1865 337 600
Fax: +44 (0)1865 337 555
www.biotrinity.com

Conference Hotel

Express by Holiday Inn
Oxford - Kassam Stadium
Grenoble Road
Oxford OX4 4XP
Tel: +44 (0)1865 780888
Fax: +44 (0)1865 780999

Quote block code "OBN" when booking to obtain a delegate discount

OBN and Destination Oxford have negotiated preferential rates with a range of hotels in Oxford. Please refer to the conference website for information on Oxford, travel, accommodation and directions.

About OBN

Catalysing the growth and development of the Oxford & South East BioCluster



OBN is the South East's leading biotech business network, catalysing the growth and development of the Oxford and the South East biotech and healthcare biotech super-cluster. Launched by Lord Sainsbury in 1999, OBN is a financially self-sustainable network which raises over 95% of its operating costs from private sources and operational activity, as well as membership. In the past 8 years, OBN has delivered over 90 meetings, attracting thousands of delegates, most notably its trademark BioTuesday biotech business networking evenings featuring key industry players from the both Oxford, UK and overseas and BioTrinity, its annual partnering conference and company showcase.

In Oxfordshire alone there are more than 150 organisations engaged in biotechnology and healthcare, with a similar number located in Surrey, Berkshire, Buckinghamshire, Hampshire, and Sussex, including several big pharma headquarters.

OBN is scheduled to spin-out as a company limited by guarantee in Q3 2008, launching its Purchasing Scheme to allow biotech companies to source lab supplies and other commodities at substantial discounts. OBN will also publish its BioCluster Report 2008 which reviews the growth and development of the BioCluster, including details of all financings, product pipelines complemented by in depth analysis. OBN also organises an exclusive senior executive dinner and a VC meeting brokerage service for SMEs.

For further information on OBN and the benefits of membership, visit www.oxfordshirebioscience.com

www.biotrinity.com



brought to you by



OBN

Suite L, Park House
11 Milton Park, Abingdon
Oxfordshire OX14 4RS
United Kingdom

Tel. +44 (0)1865 594641
Fax. +44 (0)1235 835843

Email: info@oxfordshirebioscience.net

Programme queries:

Jon Rees - Network Director

Tel. +44 (0) 1865 594642

jon.rees@oxfordshirebioscience.net
www.biotrinity.com

Event and sponsorship queries

Aruna Dudhia - Events Manager

Tel. +44 (0) 1865 594641

aruna.dudhia@oxfordshirebioscience.net
www.biotrinity.com